肝癌早期诊断及治疗--Morris Sherman教授专访
文章导读:实际上只有一种早期发现肝癌的方法,就是定期进行超声检查。许多地方对血液肿瘤标志物进行检测如甲胎蛋白以便能早期发现肿瘤,但问题是肿瘤越小,甲胎蛋白或其它标志物阳性的可能性也越小。如果真的想早期发现小肿瘤,那么真正需要使用的最敏感的检测方法就是超声。
Hepatology Digest: Early detection of HCC is obviously very important for the treatment and prognosis of HCC. Can you give us some of your suggestion and summarized for us some of the latest research related to how we can detect HCC early on?
国际肝病:显然早期发现肝癌对于治疗和预后十分重要。您能否给我们一些建议或对最新关于肝癌早期诊断的研究给我们做一些总结?
Professor Morris Sherman: There is really only one way to detect HCC early and that is to do regular ultrasound screening. Many places use blood tests such as alpha fetoprotein in an attempt to identify tumors but the problem is that the smaller the tumor, the less likely it is that the alpha-fetoprotein or any of the other markers is going to be positive. If you really want to find the smallest, earliest tumor then you really need to use the most sensitive test available, and that is the ultrasound. It should be applied regularly, every six months. There is really no benefit from using alternating strategies, which some people use, of ultrasound and alpha fetoprotein at six month intervals. The idea really is that you use your most sensitive test and apply it at the appropriate intervals.
Professor Morris Sherman: 实际上只有一种早期发现肝癌的方法,就是定期进行超声检查。许多地方对血液肿瘤标志物进行检测如甲胎蛋白以便能早期发现肿瘤,但问题是肿瘤越小,甲胎蛋白或其它标志物阳性的可能性也越小。如果真的想早期发现小肿瘤,那么真正需要使用的最敏感的检测方法就是超声。应该定期进行检测,如每6个月检查一次。一些医生使用每6个月进行超声和甲胎蛋白交替检查的策略,其实没什么益处。正确的做法是使用最敏感的检查方法,并间隔适当的时间。
Hepatology Digest: In addition to alpha fetoprotein, are there any other useful markers for early detection of HCC?
国际肝病:除甲胎蛋白外,还有没有其它对肝癌的早期诊断有用的标志物?
Professor Morris Sherman: There are other markers that are used. The PIVKA-2 or AFPL-3 are other markers that are often used, but really their effectiveness in the early detection of cancers, or screened cancers, has not been demonstrated. There is a good deal of data to suggest that they are not very good markers because alpha fetoprotein and these other two markers are also more common and more commonly expressed in advanced cancers. There is just not good in having a screening test, which detects advanced cancers because you are not going to be able to cure a large number of them. You really want a screening test which is going to pick up curable cancers, and those markers really don’t meet that criterion.
Professor Morris Sherman: 还有其它的标志物。如PIVKA-2或AFPL-3是目前经常使用的标志物,但实际上它们在早期发现癌症中的效果还没有得到证实。有大量的研究表明它们并不是很好的标志物,因为甲胎蛋白和其他两个标志物也仅仅在晚期癌症表达更加常见。如果一个检测仅仅能检测到晚期肿瘤,那么这就不是一个很好的检测,因为很多晚期肿瘤患者根本无法治愈。我们真正需要的是能够早期筛选出可治愈的肿瘤的检测方法,而这些标志物均未达到这样的标准。
Hepatology Digest: When it comes to the most effective treatment for early HCC, among surgical, non-surgical, radio frequency ablation therapy, etc. Can you talk a little about which you might currently favor? And why?
国际肝病:关于早期肝癌最有效的治疗方法,如手术,非手术,射频消融治疗等等。您能谈一下您比较倾向于选择哪种治疗方法?为什么?
Professor Morris Sherman: Depending on where you are in the world the optimal treatment of choice is different. For instance, in Japan these lesions are treated with chemoemobilization whereas most other places in the world reserve chemoembolization for more advanced tumors. The optimal treatments are probably resection and radio frequency ablation. The kinds of patients that are suitable for these two treatments are not necessarily the same, although there is some overlap. Really what you want to be able to do is to get rid of the tumor completely which resection can certainly do. There are patients whose liver disease is sufficiently advanced that resection is not possible. Those cases are obviously candidates for radio frequency ablation. There are patients who may be candidates for radio frequency ablation but have a lesion that is not accessible or likely not to be fully ablated and are obviously surgical candidates. There are also patients who could go either way.
Professor Morris Sherman: 世界上不同地区最佳的首选治疗是不同的。例如,在日本早期HCC常常选择化疗栓塞治疗,而其他大多数地方化疗栓塞常常用于治疗更晚期的肿瘤患者。最佳的治疗可能是切除术和射频消融。适合这两种治疗的患者其病情并不一定相同,尽管有一些重叠。真正要做的是彻底切除肿瘤,而根治术可以做到这一点。有些患者肝脏疾病已经发展到晚期,手术切除是不可能的。显然这些患者适合进行射频消融。有些患者虽然适合射频消融治疗但可能存在无法完全消融的病灶,显然此时适合手术治疗。也有患者任何一种治疗都可以。
Hepatology Digest: There has been some progress in HCC screening with more patients being diagnosed early so there are many changes and challenges in clinical practice. Could you give us a brief introduction on what is new in clinical practice, some of the changes you’ve observed, and any progress you think has come or will come in the future?
- 相关内容延伸阅读 ⇓
- 01. 肝癌是过度治疗的“重灾区”8532
- 02. 近年来的研究表明,复发性肝癌主要有两种来源9385
- 03. 偏食肉不吃菜肝癌高发8347
- 04. 小肝细胞癌9771
- 05. 我科学院发现人体内导致肝癌的易感基因7604
- 06. 肝癌发病机制新概念—肝细胞膜电位学说7997
热门阅读
- 01. 肝血管瘤患者常见的病因
- 02. 乙肝病人不宜房事过度
- 03. 警惕!酒精肝损伤不容小瞧
- 04. 早打乙肝疫苗,宝宝乙肝可防
- 05. 抽烟者多吃萝卜青菜护肝?坏习惯让你患上肝病
- 06. 患上乙肝大三阳早期症状有哪些
- 07. 肝病护理的三要素
- 08. 乙肝大三阳患者饮食以平淡为主
- 09. 什么是海王?海王是什么意思梗,网络流行词海王介绍
- 10. 肝炎患者在出院后该怎么护理呢
图片推荐
做乙肝检查前应注意什么?
做乙肝检查前应注意什么?乙肝五项是每年体检必做的一项检查,那么做乙肝检查前应注意什么呢?我们来简单了解一下。 1、乙肝五项检查前要空腹,虽然乙肝五项检查与肝功能检查具有着本质的区别,在空腹饮食上没有
癌症是不治之症吗?
癌症是不治之症吗?因临床很多人都对癌症不是很了解,总认为癌症是不可能治愈的,得了癌症就意味着死亡,那是事实不是这样的呢?癌症是不是不治之症呢? 癌症是不治之症吗?肝病医院专家表示:癌症并非不治之症,
右肝血管瘤
右肝血管瘤——肝脏的良性肿瘤,发展缓慢,一般肝血管瘤瘤体本身不发生癌变,且愈后良好。 右肝血管瘤——以肝海绵状血管瘤最常见,呈单发性,多数与邻近组织分界清楚。病人一般无自觉症状。 右肝血管瘤——多
何首乌及其成方制剂 有肝损伤风险
俗话说,是药三分毒,药品存在两重性,它具有治疗疾病的作用,但也存在一定的偏性和毒副作用。而前不久,国家食品药品监督总局通报了口服何首乌及其成方制剂的肝损伤风险。这一消息引发了广大市民的注意,毕竟,何首
每日饮酒多少才不会损害肝脏?
每日饮酒多少才不会损害肝脏?酒在人们的生活中占有重要的位置,有人认为少量饮酒对身体有好处,有助于防止血栓的形成,有效地防止了中风和心脏病发作的可能。那么正常人每日饮酒多少才不会损害肝脏?我们来了解一下
乙肝治疗没效果怎么办?
乙肝是临床常见的一种慢性肝病,其病程较长,且久治不愈,易反复发作,因此,很多患者失去治疗的信心,放弃了治疗,反而加速病情的发展,导致病情的恶化。那么,乙肝治疗没效果怎么办?肝病医院作出了详细的解答。
.www红色一片在线观看完整版大全-.www红色一片高清无删减免费观看完整版午夜福利大全
.www红色一片能够让你实现艾草仙姑在线视频免费观看,是年轻人手机在线观看高清福利大片的必备神器。.www红色一片里面还有二十岁电影完整版免费观看哦,简直就是你的私人影院,想看什么午夜福利高清影视,只
全球55%的肝癌患者在中国!
肝脏与心脏一样,是支撑生命大厦的重要支柱之一,这也是人们一直把心肝并称谓之宝贝的原因。 我国是肝炎大国,肝癌也是排名前列的三大癌种之一。肝癌与其他所有癌症一样,整个发病过程通常都是缓慢的,因此,预防